



Biofilm-Associated Vaginal Infections

Guest Editors:

Dr. Joana Castro

I.P.—National Institute for
Agrarian and Veterinarian
Research (INIAV), Vairão, Portugal

**Dr. José António Baptista
Machado Soares**

Microbiology Institute,
Universidad San Francisco de
Quito (USFQ), Quito, Ecuador

Prof. Dr. Christina A. Muzny

Division of Infectious Diseases,
University of Alabama at
Birmingham, Birmingham, AL
35294, USA

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editors

Bacterial vaginosis (BV) is the most common vaginal infection worldwide in women of reproductive age. Despite extensive research over the past 50 years, the etiology of BV remains unclear. However, it is certain that BV involves the presence of a multi-species biofilm on vaginal epithelial cells, where *Gardnerella* species presumably play a pivotal role.

Similar to what happens in many other biofilm infections, traditional antimicrobial therapies are unable to fully eradicate the vaginal biofilm, and unfortunately, this often leads to high recurrence rates of BV. In an attempt to overcome antimicrobial therapy failure and recurrence, new strategies including antiseptics, biofilm-disrupting agents, probiotics, endolysins, and plant-derived products, have been proposed as emergent and valuable approaches to treat BV. This Special Issue seeks manuscript submissions that further our understanding of the role of BV-associated biofilms in antimicrobial resistance. Submissions related to the response of vaginal pathogens to novel strategies that have been proposed to treat BV are especially encouraged.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi